PT  - JOURNAL ARTICLE
ED  - , 
TI  - Three More Drugs Judged “Breakthroughs”
AID  - 10.1158/2159-8290.CD-NB2013-142
DP  - 2013 Nov 01
TA  - Cancer Discovery
PG  - OF2--OF2
VI  - 3
IP  - 11
4099  - http://cancerdiscovery.aacrjournals.org/content/3/11/OF2.short
4100  - http://cancerdiscovery.aacrjournals.org/content/3/11/OF2.full
SO  - CANCER DISCOVERY2013 Nov 01; 3
AB  - The U.S. Food and Drug Administration has granted Breakthrough Therapy status to volasertib, entinostat, and alectinib, which are under development for the treatment of acute myeloid leukemia, estrogen receptor–positive breast cancer, and non–small cell lung cancer, respectively.